Accord Healthcare

Accord Healthcare company information, Employees & Contact Information

Updated June 2026

Quick answer

Accord Healthcare is a Pharmaceutical Manufacturing company. It has approximately 1,979 employees on record. Contact data was last refreshed in June 2026. Find Accord Healthcare's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Accord Healthcare is an award-winning pharmaceutical company driven to thinking differently so that more patients around the world have access to the essential and affordable medicines that they need. With operations in over 85 countries worldwide, and a pan-European footprint of more than 45 countries, Accord Healthcare develops, manufactures and distributes affordable medicines, and has one of the most active launch programmes in the European pharmaceutical sector. Life at Accord Healthcare is fast-paced and agile. We drive for results and are committed to delivering the highest possible standards because we understand that everything we do has an impact for our customers and for the patients that receive our medicines. We always strive to make it better by challenging ourselves to think differently and to deliver more every day. Whether it is product development, improving our systems and operations or building patient-focused added value services, we realise that each innovation could improve the lives of the patients who receive our medication. Living our purpose and achieving our goals means we can deliver more vital, affordable medicines to national health systems and the patients who need them most. At Accord we recognise that developing the skills and capabilities of our people is essential to the achievement of our organisation goals and we support each and every employee in doing so.

Company Details

Employees
1.98K
Address
319 Pinner Road; North Harrow, London,middlesex Ha1 4hf,united Kingdom
Phone
(919)941-7879
Email
us****@****are.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
London, Middlesex
Looking for a particular Accord Healthcare employee's phone or email?

Accord Healthcare Questions

News

Accord Healthcare Launches Dehydrated Alcohol Injection for Cardiovascular Indications - PR Newswire

Accord Healthcare Launches Dehydrated Alcohol Injection for Cardiovascular Indications PR Newswire

Belgium: Insta strengthens presence in PDMP market with acquisition of Prothya Biosolutions - Investors in Healthcare

Belgium: Insta strengthens presence in PDMP market with acquisition of Prothya Biosolutions Investors in Healthcare

Intas & Accord signs Agreement to acquire Prothya Biosolutions - PR Newswire

Intas & Accord signs Agreement to acquire Prothya Biosolutions PR Newswire

Accord Healthcare to build £50m medicines manufacturing facility in Newcastle, creating 50+ jobs - The Manufacturer

Accord Healthcare to build £50m medicines manufacturing facility in Newcastle, creating 50+ jobs The Manufacturer

Pharmaceutical Technology Excellence Awards 2023: Accord Healthcare - Pharmaceutical Technology

Pharmaceutical Technology Excellence Awards 2023: Accord Healthcare Pharmaceutical Technology

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq® - PR Newswire

Accord Healthcare Receives Positive CHMP Opinion for Denosumab, Osvyrti®, and Jubereq® PR Newswire

Accord wins £50M joint investment from UK to bolster local production of cancer, immunology drugs - Fierce Pharma

Accord wins £50M joint investment from UK to bolster local production of cancer, immunology drugs Fierce Pharma

Access to Healthcare and the Role of An Accord for a Healthier World - Pfizer

Access to Healthcare and the Role of An Accord for a Healthier World Pfizer

Accord Healthcare: Hetronifly® (Serplulimab) receives Marketing Authorisation from the European Commission (EC), for the treatment of Extensive-Stage Small Cell Lung Cancer (ES- SCLC) - PR Newswire

Accord Healthcare: Hetronifly® (Serplulimab) receives Marketing Authorisation from the European Commission (EC), for the treatment of Extensive-Stage Small Cell Lung Cancer (ES- SCLC) PR Newswire

Accord BioPharma Announces Commercial Launch of IMULDOSA® (ustekinumab-srlf) Prefilled Syringes at Lowest WAC Price Among Branded Biosimilars to STELARA® (ustekinumab) - PR Newswire

Accord BioPharma Announces Commercial Launch of IMULDOSA® (ustekinumab-srlf) Prefilled Syringes at Lowest WAC Price Among Branded Biosimilars to STELARA® (ustekinumab) PR Newswire

Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio - PR Newswire

Accord BioPharma, Inc. Announces Completion of UDENYCA® (pegfilgrastim-cbqv) Franchise Acquisition from Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio PR Newswire

Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth - PR Newswire

Accord BioPharma Announces Agreement by Intas Pharmaceuticals, Ltd. to Acquire UDENYCA® (pegfilgrastim-cbqv) Business from Coherus BioSciences, Inc., Unlocking Potential for Continued U.S. Growth PR Newswire

Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar - PR Newswire

Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar PR Newswire

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara® - PR Newswire

Accord Healthcare is granted marketing authorisation for IMULDOSA®, ustekinumab biosimilar to Stelara® PR Newswire

Accord Healthcare Inc. Announces Launch of First-to-Market Additional Strengths of Hydroxychloroquine Sulfate Tablets, in the U.S. - PR Newswire

Accord Healthcare Inc. Announces Launch of First-to-Market Additional Strengths of Hydroxychloroquine Sulfate Tablets, in the U.S. PR Newswire

Accord Healthcare Launches Generic Drug for Treating Brain Tumors & Blood Cancers - PR Newswire

Accord Healthcare Launches Generic Drug for Treating Brain Tumors & Blood Cancers PR Newswire

Accord Healthcare receives approval for Hetronifly® (Serplulimab), from the Medicines and Healthcare Regulatory Agency (MHRA) for first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PR Newswire

Accord Healthcare receives approval for Hetronifly® (Serplulimab), from the Medicines and Healthcare Regulatory Agency (MHRA) for first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) PR Newswire

Accord Healthcare Releases Generic Drug Proven Effective Against Vitamin B12 Deficiency - PR Newswire

Accord Healthcare Releases Generic Drug Proven Effective Against Vitamin B12 Deficiency PR Newswire

Accord Healthcare Offers Generic Option for Treatment of Schizophrenia and Bipolar Depression - PR Newswire

Accord Healthcare Offers Generic Option for Treatment of Schizophrenia and Bipolar Depression PR Newswire

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio - PR Newswire

Accord Healthcare Adds Pemetrexed Injection to Generic Chemotherapy Drug Portfolio PR Newswire

Accord Healthcare to offer generic schizophrenia, bipolar depression drug - Healio

Accord Healthcare to offer generic schizophrenia, bipolar depression drug Healio

Accord Healthcare Releases Generic Drug Proven Effective in Treating Major Depressive Disorder in Adults - PR Newswire

Accord Healthcare Releases Generic Drug Proven Effective in Treating Major Depressive Disorder in Adults PR Newswire

Accord Healthcare Inc - Pharmacy Times

Accord Healthcare Inc Pharmacy Times

Accord for a Healthier World - Pfizer

Accord for a Healthier World Pfizer

Esperion Settles Patent Litigation with Accord Healthcare to Protect NEXLETOL Until 2040 - Nasdaq

Esperion Settles Patent Litigation with Accord Healthcare to Protect NEXLETOL Until 2040 Nasdaq

FDA Approves IMULDOSA™ (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA® (ustekinumab), for the Treatment of Chronic Inflammatory Conditions - PR Newswire

FDA Approves IMULDOSA™ (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA® (ustekinumab), for the Treatment of Chronic Inflammatory Conditions PR Newswire

Accord Healthcare: Consistent, quality and agile supply in a crowded market - Supply Chain Digital

Accord Healthcare: Consistent, quality and agile supply in a crowded market Supply Chain Digital

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, ustekinumab biosimilar to Stelara® - PR Newswire

Accord Healthcare receives positive CHMP opinion for IMULDOSA®, ustekinumab biosimilar to Stelara® PR Newswire

Accord Healthcare launches Disulfiram in the United Kingdom, indicated as a supportive agent in the treatment of alcoholism - Yahoo Finance

Accord Healthcare launches Disulfiram in the United Kingdom, indicated as a supportive agent in the treatment of alcoholism Yahoo Finance

Esperion settles litigation with Accord Healthcare (ESPR) - Seeking Alpha

Esperion settles litigation with Accord Healthcare (ESPR) Seeking Alpha

MHRA approves Accord Healthcare’s Hetronifly to treat aggressive form of lung cancer - PMLiVE

MHRA approves Accord Healthcare’s Hetronifly to treat aggressive form of lung cancer PMLiVE

Patent case: Novartis Pharmaceuticals Corporation. v. Accord Healthcare, Inc., USA - Wolters Kluwer

Patent case: Novartis Pharmaceuticals Corporation. v. Accord Healthcare, Inc., USA Wolters Kluwer

Accord BioPharma, Inc. Recognizes Milestone as More Than 10,000 Patients Gain Access to CAMCEVI® (leuprolide) - PR Newswire

Accord BioPharma, Inc. Recognizes Milestone as More Than 10,000 Patients Gain Access to CAMCEVI® (leuprolide) PR Newswire

Myovant Sciences and Accord Healthcare, Ltd. Enter into - GlobeNewswire

Myovant Sciences and Accord Healthcare, Ltd. Enter into GlobeNewswire

Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer - PR Newswire

Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of 420mg Strength of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab), for the Treatment of Several Forms of HER2-Overexpressing Cancer PR Newswire

Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab) for the Treatment of Several Forms of HER2-Overexpressing Cancer - PR Newswire

Accord BioPharma, Inc. Announces U.S. Food & Drug Administration Approval of HERCESSI™ (trastuzumab-strf), a biosimilar to Herceptin® (trastuzumab) for the Treatment of Several Forms of HER2-Overexpressing Cancer PR Newswire

Accord Healthcare’s Tacrolimus Oral Capsules No Longer Substitutable for Prograf - Medical Professionals Reference

Accord Healthcare’s Tacrolimus Oral Capsules No Longer Substitutable for Prograf Medical Professionals Reference

Amid shortage, Accord Healthcare restarts production of cancer drug cisplatin - Fierce Pharma

Amid shortage, Accord Healthcare restarts production of cancer drug cisplatin Fierce Pharma

Accord Healthcare - Pharmacy Times

Accord Healthcare Pharmacy Times

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 mg due to labeling mix-up - PR Newswire

Accord Healthcare Inc. Issues Voluntary Nationwide Recall of Hydrochlorothiazide Tablets USP 12.5 mg due to labeling mix-up PR Newswire

Veloxis Files Suit Against Accord Healthcare and Intas Pharmaceuticals in Patent Infringement Case - Law Street Media

Veloxis Files Suit Against Accord Healthcare and Intas Pharmaceuticals in Patent Infringement Case Law Street Media

Why a patient-centric approach to medical innovation is essential - Raconteur

Why a patient-centric approach to medical innovation is essential Raconteur

New hires at Bayer, Eisai and Accord Healthcare - PMLiVE

New hires at Bayer, Eisai and Accord Healthcare PMLiVE

Denosumab Biosimilars Earn Positive CHMP Opinion for Osteoporosis and Cancer-Related Bone Disease - OncLive

Denosumab Biosimilars Earn Positive CHMP Opinion for Osteoporosis and Cancer-Related Bone Disease OncLive

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions - PR Newswire Canada

Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions PR Newswire Canada

Accord Healthcare launches Accord Animal Health - PR Newswire UK

Accord Healthcare launches Accord Animal Health PR Newswire UK

Patent case: Accord Healthcare Ltd. vs. Shire-NPS Pharmaceuticals Inc., Netherlands - Wolters Kluwer

Patent case: Accord Healthcare Ltd. vs. Shire-NPS Pharmaceuticals Inc., Netherlands Wolters Kluwer

Accord Healthcare opens new pharmaceutical facility in Newcastle - Manufacturing Digital Magazine

Accord Healthcare opens new pharmaceutical facility in Newcastle Manufacturing Digital Magazine

Anthony Grosso new head of scientific affairs at Accord Healthcare - PharmaTimes

Anthony Grosso new head of scientific affairs at Accord Healthcare PharmaTimes

Accord Healthcare launches Herceptin biosimilar in the UK - PharmaTimes

Accord Healthcare launches Herceptin biosimilar in the UK PharmaTimes

Peter Kelly named managing director of Accord Healthcare UK - PMLiVE

Peter Kelly named managing director of Accord Healthcare UK PMLiVE

Accord Healthcare launches thalidomide for multiple myeloma treatment - Pharmafile

Accord Healthcare launches thalidomide for multiple myeloma treatment Pharmafile

Recognising the benefits of prostate cancer support groups - The Times

Recognising the benefits of prostate cancer support groups The Times

Independent pharmacists share their positive experiences of working with Accord Healthcare - Irish Medical Times

Independent pharmacists share their positive experiences of working with Accord Healthcare Irish Medical Times

Accord Healthcare case successfully resolved - Hospital Pharmacy Europe

Accord Healthcare case successfully resolved Hospital Pharmacy Europe

Accord Healthcare launch Bendamustine 25mg/ml concentrate for solution for infusion - Irish Medical Times

Accord Healthcare launch Bendamustine 25mg/ml concentrate for solution for infusion Irish Medical Times

Court of Appeal upholds enzalutamide patent validity in Accord Healthcare dispute - Solicitors Journal

Court of Appeal upholds enzalutamide patent validity in Accord Healthcare dispute Solicitors Journal

Accord Healthcare Ireland launch Azacitidine Accord powder - Irish Medical Times

Accord Healthcare Ireland launch Azacitidine Accord powder Irish Medical Times

Accord Healthcare launch Tigecycline Accord 50mg powder for solution for infusion - Irish Medical Times

Accord Healthcare launch Tigecycline Accord 50mg powder for solution for infusion Irish Medical Times

Accord Healthcare receives approval for Hetronifly® (Serplulimab), from the Medicines and Healthcare Regulatory Agency (MHRA) for first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - Adnkronos

Accord Healthcare receives approval for Hetronifly® (Serplulimab), from the Medicines and Healthcare Regulatory Agency (MHRA) for first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Adnkronos

Accord Healthcare opens job-creating Newcastle site - Insider Media Ltd

Accord Healthcare opens job-creating Newcastle site Insider Media Ltd

Top Accord Healthcare Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant